javascript:void(0);
javascript:void(0);
Welcome to Oyster Biopharma, where pioneering science meets compassionate care. Our flagship product, OP-01, is a groundbreaking investigational therapy designed to address the challenges of dry eye disease. Through innovative eyelid nerve stimulation, OP-01 triggers sustained tear production, offering hope to patients worldwide.
At Oyster Biopharma, we're dedicated to advancing the forefront of dry eye treatment. Our commitment to excellence is evident in every phase of our development process, including rigorous Phase 3 trials to ensure the safety and efficacy of OP-01. Through meticulous research and development, we aim to bring transformative therapies to those in need.
Driven by a passion for innovation and a commitment to improving patient outcomes, Oyster Biopharma is shaping the future of biopharmaceuticals. Our investigational therapy, OP-01, represents a new frontier in dry eye treatment, offering a ray of hope to those who suffer from this chronic condition.
Located at the intersection of cutting-edge science and patient-centric care, Oyster Biopharma is dedicated to improving lives through innovative solutions. Join us on our journey to redefine the standard of care for dry eye disease, one breakthrough at a time.